Muscle in Obesity: Imaging, Function and microRNA
1 other identifier
observational
30
1 country
1
Brief Summary
Growing evidence suggests that dynapenic abdominal obesity is associated with a greater risk of falls, functional disability and hospitalisation compared to those with dynapenia, obesity or neither phenotype. Understanding the pathogenesis underlying this phenotype has the potential to inform potential treatment strategies. MicroRNAs can act as messengers at the cellular level to promote or block processes for muscle growth and repair, amongst other things. There is evidence that ageing changes microRNA levels in the muscle and that these changes may result in reduced muscle quality and quantity. However, it is not known whether being obese can change microRNA levels in muscle and how this relates to physical performance. The aim of this study is to investigate the effect of dynapenic abdominal obesity on microRNA levels in serum and muscle quality and quantity in the legs of older women. This is an observational, cross-sectional study. The investigators will recruit 4 groups of older women: normal weight, normal weight with dynapenia, obese and obese with dynapenia. The investigators will measure the microRNA levels in serum. The investigators will measure the quantity and fat content of muscle in the legs using magnetic resonance imaging. Muscle strength, fatigue and balance will be measured using gait (walking) analysis, balance tests, and a machine designed to measure leg strength and fatigue. The investigators will measure and compare microRNA levels between groups. The investigators will use databases and computer programmes to look at all of the microRNAs which are different between groups and see how they affect the muscle. The investigators will compare muscle strength, size and fatigue between groups. The investigators will explore relationships of muscle quantity and quality measures with microRNA changes in the muscle. This approach will allow the investigators to understand how obesity affects the microRNA profile of muscle and whether this translates into impairment of function and mobility.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Sep 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 19, 2019
CompletedFirst Posted
Study publicly available on registry
March 9, 2020
CompletedStudy Start
First participant enrolled
September 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 17, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
March 17, 2023
CompletedNovember 18, 2023
November 1, 2023
1.5 years
December 19, 2019
November 15, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Differential microRNA expression, expressed as fold-change and p-values, measured using real time quantitative polymerase chain reaction (RT-qPCR) between normal weight and obese groups, further stratified by dynapenia
Serum analyses
1 day (one measurement )
Secondary Outcomes (5)
mean difference in distance walked during 6 minute walk test between normal weight and obese, further stratified by dynapenia
1 day (one measurement )
mean difference in muscle mass and volume measures between normal weight and obese, further stratified by dynapenia MRI
1 day (one measurement )
mean difference in muscle mass and volume measures between normal weight and obese, further stratified by dynapenia DXA
1 day (one measurement )
mean difference in muscle strength between normal weight and obese, further stratified by dynapenia
1 day (one measurement )
mean difference in fatigue between normal weight and obese, further stratified by dynapenia
1 day (one measurement )
Study Arms (4)
normal weight, not dynapenic
BMI 18.5 to 25kg/m2, waist circumference \<= 88cm, healthy women aged 60-80 years, time to complete 5 chair stands \<15 seconds
normal weight, dynapenic
BMI 18.5 to 25kg/m2, waist circumference \<= 88cm,healthy women aged 60-80 years, time to complete 5 chair stands \>15 seconds
obese, not dynapenic
BMI 30 to 40kg/m2, waist circumference \> 88cm, healthy women aged 60-80 years, time to complete 5 chair stands \<15 seconds
obese, dynapenic
BMI 30 to 40kg/m2, waist circumference \> 88cm, women aged 60-80 years, time to complete 5 chair stands \>15 seconds
Interventions
observational study
Eligibility Criteria
Healthy Caucasian Women Recruited from around South Yorkshire and Merseyside, UK
You may qualify if:
- Caucasian
- Female
- BMI 18.5-25 or 30-40kg/m2
- Ages 60-80 years
- Sufficiently mobile to undergo scanning and biomechanical testing
- Able to remain motionless during scans
- Able and willing to participate in the study and provide written informed consent
You may not qualify if:
- BMI 18.5-25kg/m2 AND waist circumference \>88cm i.e. normal weight AND abdominally obese
- BMI 30-40kg/m2 AND waist circumference \<88cm i.e. obese AND not abdominally obese
- History of any long-term immobilisation (duration greater than 2 weeks in the past 12 months)
- History of hospital admission in the past 3 months
- History of recent significant weight loss (5% in 3 months or 10% in 6 months)
- Diabetes mellitus
- History of current conditions which may affect muscle metabolism
- Malabsorption syndromes e.g. inflammatory bowel disease, pancreatic insufficiency etc.
- Chronic renal disease
- Diagnosed eating disorder
- Conditions which prevent the undertaking or analysis of the MRI and DXA scans or the interpretation of their results e.g. hip prosthesis, metal implants etc.
- Conditions which prevent the undertaking of the fatigue protocols e.g. hypertension etc.
- Use of medications or treatment known to affect muscle metabolism
- o Anabolic steroids, glucocorticoids, antiretrovirals etc.
- Excessive alcohol intake defined as greater than 21 units per week
- +2 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sheffield Teaching Hospitals NHS Foundation Trustlead
- University of Sheffieldcollaborator
- University of Liverpoolcollaborator
Study Sites (1)
University of Sheffield/Sheffield Teaching Hospitals
Sheffield, South Yorkshire, United Kingdom
Biospecimen
Serum
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jennifer Walsh
University of Sheffield
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 19, 2019
First Posted
March 9, 2020
Study Start
September 1, 2021
Primary Completion
March 17, 2023
Study Completion
March 17, 2023
Last Updated
November 18, 2023
Record last verified: 2023-11